Drug intelligence / Profile preview

PEP-3 vaccine + sargramostim + temozolomide

Development stage: Unknown
Lead developer: Duke University Medical Center
Modality: Recombinant Proteins and Enzymes, Small Molecules, Vaccines & Immunotherapeutics
Administration: Intradermal, Oral

Overview

A combination therapy consisting of PEP-3 vaccine (a synthetic peptide vaccine targeting EGFRvIII), sargramostim (GM-CSF, an immune stimulant), and temozolomide (an oral alkylating chemotherapy agent). This regimen is primarily studied for the treatment of glioblastoma multiforme. The PEP-3 vaccine consists of a 13-amino acid peptide conjugated to keyhole limpet hemocyanin (KLH) to enhance immunogenicity. Sargramostim is used as an adjuvant to boost immune response, while temozolomide provides direct cytotoxic effects against tumor cells.

Other names: PEP-3-KLH conjugate vaccine + sargramostim + temozolomide

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)EGFRvIII (Epidermal growth factor receptor variant III)

Beyond the preview

Go deeper on PEP-3 vaccine + sargramostim + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEP-3 vaccine + sargramostim + temozolomide.

Explore the full profile